In the case of AFP, GPC3 and SALL4, the boundary between diagnostic biomarkers and therapeutic targeting are increasingly blurred, and these proteins have emerged as biomarker-guided HCC precision medicine. This evidence concerns the gene GPC3 and hepatocellular carcinoma.